Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation.
Sarah SkeochP L Hubbard CristinacceH WilliamsP PembertonD XuJ SunJ JamesC YuanT HatsukamiP D HockingsM Y AlexanderJohn Charles WatertonI N BrucePublished in: Scientific reports (2017)
In rheumatoid arthritis (RA), chronic inflammation is thought to drive increased cardiovascular risk through accelerated atherosclerosis. It may also lead to a more high-risk plaque phenotype. We sought to investigate carotid plaque phenotype in RA patients using Dynamic Contrast-Enhanced MRI (DCE-MRI) and Fludeoxyglucose Positron Emission Tomography(FDG-PET). In this pilot study, RA patients and age/sex-matched controls were evaluated for cardiovascular risk factors and carotid plaque on ultrasound. Subjects with plaque >2 mm thick underwent DCE-MRI, and a subgroup of patients had FDG-PET. Comparison of MRI findings between groups and correlation between clinical, serological markers and imaging findings was undertaken. 130 patients and 62 controls were recruited. Plaque was more prevalent in the RA group (53.1% vs 37.0%, p = 0.038) and was independently associated with IL6 levels (HR[95%CI]: 2.03 [1.26, 3.26] per quartile). DCE-MRI data were available in 15 patients and 5 controls. Higher prevalence of plaque calcification was noted in RA, despite similar plaque size (73.3% vs 20%, p = 0.04). FDG-PET detected plaque inflammation in 12/13 patients scanned and degree of inflammation correlated with hs-CRP (r = 0.58, p = 0.04). This study confirms increased prevalence of atherosclerosis in RA and provides data to support the hypothesis that patients have a high-risk plaque phenotype.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- positron emission tomography
- ejection fraction
- newly diagnosed
- magnetic resonance imaging
- computed tomography
- coronary artery disease
- cardiovascular disease
- peritoneal dialysis
- type diabetes
- pet ct
- cardiovascular risk factors
- interstitial lung disease
- mass spectrometry
- risk factors
- disease activity
- patient reported outcomes
- systemic sclerosis
- ankylosing spondylitis
- idiopathic pulmonary fibrosis
- data analysis
- electronic health record
- open label
- drug induced
- phase iii